Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CMV-VST

PreclinicalBiologic

UUniversity of Calgary

CMV-VST is one of 43 biologic programs targeting Immunodeficiency. It is currently in Preclinical.

1

Indications

1

Total Trials

1

Active Trials

42

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunodeficiencyActive, not recruiting

ImmunodeficiencyPreclinical

Active, not recruiting

Competition

Competitive Landscape

46 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

Fuzeon

CConrado Roberto Hoffmann Filho

Adenocard

Viramune

Boehringer Ingelheim

Busulfex

Akero Therapeutics

Rayos

RRoxane Laboratories

Cabenuva

Immunoglobulin

Cytosar

Vepesid

Bicnu

MMelissa K Accordino

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2040

N/AActive, not recruiting

Immunodeficiency

NCT07015801

Clinical

Trials by Indication[1]

Immunodeficiency1 trial

CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency

Active, not recruiting·UUniversity of Calgary·N/A·NCT07015801·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CMV-VST. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CMV-VST compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CMV-VST. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Calgary company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Calgary

Related News